دورية أكاديمية
أعرض في EDS

Cancer and Mortality Risks of Graves' Disease in South Korea Based on National Data from 2010 to 2019.

التفاصيل البيبلوغرافية
العنوان: Cancer and Mortality Risks of Graves' Disease in South Korea Based on National Data from 2010 to 2019.
المؤلفون: Choi YJ; Department of Pediatrics, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea., Han K; Department of Statistics and Actuarial Science, College of Natural Sciences, Soongsil University, Seoul, Republic of Korea., Cho WK; Department of Pediatrics, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea., Jung MH; Department of Pediatrics, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea., Suh BK; Department of Pediatrics, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
المصدر: Clinical epidemiology [Clin Epidemiol] 2023 May 02; Vol. 15, pp. 535-546. Date of Electronic Publication: 2023 May 02 (Print Publication: 2023).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Dove Medical Press Country of Publication: New Zealand NLM ID: 101531700 Publication Model: eCollection Cited Medium: Print ISSN: 1179-1349 (Print) Linking ISSN: 11791349 NLM ISO Abbreviation: Clin Epidemiol Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Auckland, N.Z.] : Dove Medical Press, c2009-
مستخلص: Purpose: This study aimed to investigate Graves' disease (GD) associated cancer and mortality risk using a Korean population-based study.
Patients and Methods: We included 6435 patients with GD using the Korean National Health Insurance Service-National Sample Cohort database from 2010 to 2019. Data concerning such patients were compared in a 1:5 ratio with age- and sex-matched non-GD group (n=32,175). Eighteen subdivided types of cancer and cancers-in-total were analyzed. In addition to the mortality analysis, subgroup analyses were performed according to age and sex.
Results: After adjustment, the hazard ratio (HR) of the GD group for cancer-in-total was 1.07 (95% confidence interval [CI], 0.91-1.27), showing no difference when compared to the non-GD group. However, among different types of cancer, the thyroid cancer risk of the GD group was higher than that of the non-GD group (HR=1.70; 95% CI, 1.20-2.39). When subdivided by age and sex, the thyroid cancer risk of the GD group in males aged 20-39 years was higher than that of the non-GD group (HR=7.00; 95% CI, 1.48-33.12). The mortality risk of the GD group was not different from that of the non-GD group (HR=0.86; 95% CI, 0.70-1.05).
Conclusion: In South Korea, patients with GD had a higher risk of thyroid cancer than the non-GD group. In particular, males aged 20-39 years with GD were more likely to have thyroid cancer than the non-GD group.
Competing Interests: The authors report no conflicts of interest in this work.
(© 2023 Choi et al.)
References: Front Endocrinol (Lausanne). 2019 Jul 17;10:482. (PMID: 31379748)
Eur J Endocrinol. 2014 Feb 04;170(3):419-27. (PMID: 24366943)
Endocrinol Metab (Seoul). 2018 Jun;33(2):260-267. (PMID: 29947180)
Diabetes Care. 2012 Nov;35(11):2402-11. (PMID: 23093685)
Autoimmun Rev. 2015 Feb;14(2):174-80. (PMID: 25461470)
World J Surg Oncol. 2020 Oct 13;18(1):266. (PMID: 33050937)
Thyroid. 1998 Sep;8(9):751-4. (PMID: 9777744)
Hum Reprod Update. 2005 Jul-Aug;11(4):411-23. (PMID: 15817524)
Semin Cancer Biol. 2020 Aug;64:135-146. (PMID: 31158464)
Endocrinol Metab (Seoul). 2022 Oct;37(5):791-799. (PMID: 36220137)
Int J Epidemiol. 2017 Jun 1;46(3):799-800. (PMID: 27794523)
Ther Clin Risk Manag. 2014 Mar 03;10:151-63. (PMID: 24623979)
Int J Epidemiol. 2017 Apr 1;46(2):e15. (PMID: 26822938)
JAMA Pediatr. 2016 Oct 01;170(10):1008-1019. (PMID: 27571216)
Eur J Endocrinol. 2018 Oct 12;179(5):R261-R274. (PMID: 30320502)
Int J Surg. 2016 Mar;27:118-125. (PMID: 26626367)
N Engl J Med. 2016 Oct 20;375(16):1552-1565. (PMID: 27797318)
Endocrine. 2019 Sep;65(3):616-622. (PMID: 31065912)
Endocrinol Metab (Seoul). 2021 Dec;36(6):1268-1276. (PMID: 34823306)
J Lipids. 2011;2011:575840. (PMID: 21789282)
Thyroid. 2017 Dec;27(12):1475-1480. (PMID: 29084476)
J Clin Endocrinol Metab. 2012 Aug;97(8):2661-9. (PMID: 22569239)
Thyroid. 2020 Mar;30(3):357-364. (PMID: 31973681)
Gland Surg. 2021 Jan;10(1):336-346. (PMID: 33633990)
Nat Rev Dis Primers. 2020 Jul 2;6(1):52. (PMID: 32616746)
Thyroid. 2013 Apr;23(4):408-13. (PMID: 23253072)
Cancer Epidemiol Biomarkers Prev. 2017 Aug;26(8):1209-1218. (PMID: 28377419)
Exp Clin Endocrinol Diabetes. 2013 Jul;121(7):402-6. (PMID: 23616188)
PLoS One. 2013 Jun 20;8(6):e66711. (PMID: 23818961)
Ann Oncol. 2006 Jan;17(1):60-4. (PMID: 16282247)
J Clin Endocrinol Metab. 2018 Jun 1;103(6):2216-2224. (PMID: 29590402)
Br J Cancer. 2010 Apr 27;102(9):1397-9. (PMID: 20354521)
J Clin Endocrinol Metab. 2014 Mar;99(3):923-31. (PMID: 24423323)
Clin Endocrinol (Oxf). 1977 Dec;7(6):481-93. (PMID: 598014)
Oncogene. 2002 Jan 24;21(5):761-8. (PMID: 11850804)
Diabetes Metab J. 2014 Oct;38(5):395-403. (PMID: 25349827)
J Diabetes Res. 2013;2013:390534. (PMID: 23671867)
Future Oncol. 2010 Nov;6(11):1771-9. (PMID: 21142662)
Endocrinol Metab (Seoul). 2014 Sep;29(3):257-69. (PMID: 25309784)
BMJ Open. 2018 Mar 30;8(3):e020194. (PMID: 29602850)
Ann Rheum Dis. 2011 Jan;70(1):151-6. (PMID: 20881011)
Cancer. 2017 Dec 15;123(24):4808-4814. (PMID: 28817188)
Clin Endocrinol (Oxf). 2004 Jun;60(6):719-25. (PMID: 15163336)
Thyroid. 2017 Aug;27(8):1001-1010. (PMID: 28578598)
Thyroid. 2013 Jul;23(7):879-84. (PMID: 23421548)
Thyroid. 2020 Oct;30(10):1496-1504. (PMID: 32524894)
فهرسة مساهمة: Keywords: Graves disease; Republic of Korea; mortality; neoplasms
تواريخ الأحداث: Date Created: 20230509 Latest Revision: 20230511
رمز التحديث: 20230512
مُعرف محوري في PubMed: PMC10163882
DOI: 10.2147/CLEP.S406361
PMID: 37159800
قاعدة البيانات: MEDLINE
الوصف
تدمد:1179-1349
DOI:10.2147/CLEP.S406361